{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:26:23Z","timestamp":1774578383178,"version":"3.50.1"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alberta SPOR SUPPORT Unit"},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Despite emerging evidence for new pharmacotherapies to improve outcomes in patients with heart failure (HF) and kidney dysfunction, data on contemporary HF therapy use in this population are lacking. This study evaluated contemporary longitudinal treatment patterns in patients with HF across the spectrum of kidney function and left ventricular ejection fraction (LVEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a prospective, observational cohort of 1401 HF patients, we examined HF therapy use over 2 years and dose intensity stratified by ambulatory estimated glomerular filtration rate (eGFR \u226560, 30 to &amp;lt;60 and &amp;lt;30 mL\/min\/1.73 m2) and HF with reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction. Clinical outcomes, incidence of hyperkalaemia (serum potassium &amp;gt; 5.5 mmol\/L) and clinician-reported reasons for underutilizing HF therapies were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median age was 68 (58 to 76) years; 29% were female; 54%, 37% and 9% had an eGFR of \u226560, 30 to &amp;lt;60 and &amp;lt;30, respectively. Among patients with eGFR \u226560, 95%, 94%, 75% and 15% were on a beta-blocker (BB), renin\u2013angiotensin system inhibitor (RASi), mineralocorticoid receptor antagonist (MRA) and sodium glucose cotransporter-2 inhibitor, respectively. In patients with eGFR &amp;lt;30, corresponding baseline rates were 88%, 68%, 35% and 7%. Utilization rates were similar in patients with eGFR 30 to &amp;lt;60 compared with eGFR \u226560; however, fewer patients were on guideline-directed dose intensities with 44% versus 57% for RASi and 19% versus 26% for MRA. However, &amp;gt;90% of patients were on a BB, with similar utilization rates across HF and eGFR categories. Baseline ARNI use was 29%, 24% and 11% in eGFR \u226560, 30 to &amp;lt;60 and &amp;lt;30, respectively. Trends in HF therapy use persisted over 2 years. Among patients with eGFR &amp;lt;30, kidney dysfunction was the most frequently cited reason for underutilizing RASi. Patients with eGFR &amp;lt;60 experienced higher all-cause mortality, hospitalization and higher rates of hyperkalaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gaps in HF therapy use persist in patients with comorbid kidney dysfunction. Targeted strategies to implement new therapies and improve adherence to HF treatments are necessary to improve outcomes in a highly comorbid and at-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.70008","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:15:54Z","timestamp":1763349354000},"page":"4431-4441","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapy Gaps for Patients with Heart Failure and Reduced Kidney Function: A Prospective Cohort Study"],"prefix":"10.1093","volume":"12","author":[{"given":"Chen Hsiang","family":"Ma","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Qi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiming","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandu","family":"Sadasivan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anukul","family":"Ghimire","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Faculty of Medicine, University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Cooper","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Nephrology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Somkanya","family":"Tungsanga","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Immunology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]},{"name":"Division of General Internal Medicine-Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventure","family":"Oguaju","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Immunology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Vandermeer","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Immunology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finlay A.","family":"McAlister","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, University of Alberta , Edmonton, Alberta ,","place":["Canada"]},{"name":"The Alberta Strategy for Patient Oriented Research Support Unit (AbSPORU) , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aminu K.","family":"Bello","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Immunology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Alberta ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"2026021804162128000_ehf270008-bib-0001","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jchf.2024.11.007","article-title":"Outcomes of KDIGO-defined CKD in U.S. veterans with HFpEF, HFmrEF, and HFrEF","volume":"13","author":"Patel","year":"2025","journal-title":"JACC: Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0002","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1002\/ehf2.14933","article-title":"Incidence of clinical outcomes in heart failure patients with and without advanced chronic kidney disease","volume":"11","author":"Zahir Anjum","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0003","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0004","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1161\/CIRCULATIONAHA.121.052792","article-title":"Evidence-based medical therapy in patients with heart failure with reduced ejection fraction and chronic kidney disease","volume":"145","author":"Beldhuis","year":"2022","journal-title":"Circulation"},{"key":"2026021804162128000_ehf270008-bib-0005","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ehf2.12185","article-title":"Impaired renal function affects clinical outcomes and management of patients with heart failure","volume":"4","author":"Jenkins","year":"2017","journal-title":"ESC Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0006","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"Kdigo 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work G","year":"2021","journal-title":"Kidney Int"},{"key":"2026021804162128000_ehf270008-bib-0007","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1111\/dom.15194","article-title":"Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD registry, 2019\u20132020","volume":"25","author":"Nicholas","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026021804162128000_ehf270008-bib-0008","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ahj.2024.04.007","article-title":"Uptake of SGLT2i and outcomes in patients with diabetes and heart failure: a population-based cohort and a specialized clinic cohort","volume":"274","author":"Gagnon","year":"2024","journal-title":"Am Heart J"},{"key":"2026021804162128000_ehf270008-bib-0009","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"2026021804162128000_ehf270008-bib-0010","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026021804162128000_ehf270008-bib-0011","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804162128000_ehf270008-bib-0012","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jacc.2021.05.002","article-title":"Kidney function and outcomes in patients hospitalized with heart failure","volume":"78","author":"Patel","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026021804162128000_ehf270008-bib-0013","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0014","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/eurheartj\/ehr238","article-title":"Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial","volume":"32","author":"Blair","year":"2011","journal-title":"Eur Heart J"},{"key":"2026021804162128000_ehf270008-bib-0015","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011173","article-title":"Risk factors and outcomes associated with heart failure with preserved and reduced ejection fraction in people with chronic kidney disease","volume":"17","author":"Bansal","year":"2024","journal-title":"Circulation: Heart Failure"},{"key":"2026021804162128000_ehf270008-bib-0016","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1002\/ehf2.13417","article-title":"Cardiac reverse remodelling and health status in patients with chronic heart failure","volume":"8","author":"Wang","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0017","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804162128000_ehf270008-bib-0018","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804162128000_ehf270008-bib-0019","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0020","doi-asserted-by":"publisher","first-page":"130","DOI":"10.15420\/cfr.2019.8.2","article-title":"Hyperkalemia and renin\u2013angiotensin-aldosterone system inhibitors dose therapy in heart failure with reduced ejection fraction","volume":"5","author":"Rosano","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026021804162128000_ehf270008-bib-0021","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/ehf2.15049","article-title":"Real-world data on empagliflozin and dapagliflozin use in patients with HEART failure: the RED\u2013HEART study","volume":"12","author":"Kocabas","year":"2025","journal-title":"ESC Heart Failure"},{"key":"2026021804162128000_ehf270008-bib-0022","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jchf.2024.03.014","article-title":"Sacubitril\/valsartan in patients with heart failure and deterioration in eGFR to &lt;30 mL\/min\/1.73 m2","volume":"12","author":"Chatur","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0023","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.jacc.2024.03.392","article-title":"Effects of sacubitril\/valsartan across the spectrum of renal impairment in patients with heart failure","volume":"83","author":"Chatur","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021804162128000_ehf270008-bib-0024","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026021804162128000_ehf270008-bib-0025","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The E-KCG","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021804162128000_ehf270008-bib-0026","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804162128000_ehf270008-bib-0027","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2026021804162128000_ehf270008-bib-0028","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804162128000_ehf270008-bib-0029","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540453","article-title":"Patiromer-facilitated renin\u2013angiotensin-aldosterone system inhibitor utilization in patients with heart failure with or without comorbid chronic kidney disease: subgroup analysis of DIAMOND randomized trial","volume":"55","author":"Weir","year":"2024","journal-title":"Am J Nephrol"},{"key":"2026021804162128000_ehf270008-bib-0030","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021804162128000_ehf270008-bib-0031","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jacc.2025.01.011","article-title":"Do potassium binders block both the benefits and the risks of mineralocorticoid receptor antagonists in heart failure?: The four anti-aldosterone myths","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026021804162128000_ehf270008-bib-0032","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/sj.ki.5001835","article-title":"Beta blockers in the management of chronic kidney disease","volume":"70","author":"Bakris","year":"2006","journal-title":"Kidney Int"},{"key":"2026021804162128000_ehf270008-bib-0033","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/europace\/euz358","article-title":"Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association\/European Dialysis and Transplantation Association (ERA\/EDTA) physician-based survey","volume":"22","author":"Potpara","year":"2020","journal-title":"Europace"},{"key":"2026021804162128000_ehf270008-bib-0034","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0035","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","article-title":"Contemporary use and implications of Beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial","volume":"12","author":"Peikert","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021804162128000_ehf270008-bib-0036","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/ndt\/gfz167","article-title":"The association of beta-blocker use with mortality in elderly patients with congestive heart failure and advanced chronic kidney disease","volume":"35","author":"Molnar","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804162128000_ehf270008-bib-0037","doi-asserted-by":"publisher","first-page":"E1000","DOI":"10.1503\/cmaj.221018","article-title":"Prevalence and predictors of primary nonadherence to medications prescribed in primary care","volume":"195","author":"Zeitouny","year":"2023","journal-title":"CMAJ"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4431\/66968177\/eschf_12_6_4431.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4431\/66968177\/eschf_12_6_4431.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:16:28Z","timestamp":1771406188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4431\/8488166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11,16]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.70008","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"2025-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}